Relapsed or Refractory B-cell Lymphoma Clinical Trial
Official title:
Exploratory Study of a Novel Oncolytic Vaccinia Virus Expressing Bispecific Antibody in the Treatment of Refractory/Relapsed B-cell Lymphoma
This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,
Oncolytic vaccinia virus administered by intratumoral injection ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04056975 -
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT06062641 -
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
|
Phase 2 | |
| Recruiting |
NCT05806580 -
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
|
Phase 4 | |
| Recruiting |
NCT03208556 -
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT05814848 -
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
|
Phase 4 | |
| Recruiting |
NCT03391726 -
CART-19 Cells for R/R B-cell Lymphoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05720052 -
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06045585 -
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
|
Early Phase 1 |